Liver cancer most often develops in a liver already damaged by chronic disease, with viral hepatitis, heavy alcohol use, and increasingly fatty liver disease accounting for the vast majority of cases worldwide. Hepatocellular carcinoma (HCC) makes up roughly three-quarters of all primary liver cancers, and because it tends to be diagnosed late, outcomes depend heavily on catching it before symptoms appear. The causes, diagnostic tools, and treatment landscape have shifted substantially in the past decade, with new immunotherapy combinations improving survival for advanced disease and public health measures like hepatitis B vaccination cutting incidence in entire populations.
Primary Liver Cancer Versus Cancer That Spreads to the Liver
A key distinction that often confuses people: the liver is both the sixth most common site of primary cancer and one of the organs most frequently colonized by cancers that start elsewhere. Colorectal, breast, lung, and pancreatic cancers all commonly metastasize to the liver because of its rich blood supply and unique immune environment.1Nature Reviews Cancer. The immunological and metabolic landscape in primary and metastatic liver cancer These metastatic liver tumors are not liver cancer; they are treated according to the rules of whatever organ they originated in.
Primary liver cancers and metastatic liver tumors look different on imaging. Metastases tend to show up as multiple lesions with irregular borders and a characteristic rim of contrast enhancement, while primary liver cancers are more often solitary, with smooth margins, strong arterial-phase contrast uptake, and washout in later imaging phases. Elevated blood levels of alpha-fetoprotein (AFP) above 400 ng/mL strongly favor a primary liver cancer diagnosis. Combining imaging features can distinguish the two with high accuracy.2PubMed Central. Differentiating Liver Metastases from Primary Liver Cancer: A Retrospective Study of Imaging and Pathological Features in Patients with Histopathological Confirmation When referring to “liver cancer” in the rest of this article, the focus is on HCC and other primary liver cancers, not metastatic disease.
What Causes Most Liver Cancers
Almost every case of HCC develops in a liver that has been chronically inflamed for years or decades. That inflammation causes repeated cycles of liver cell death and regeneration, and over time the accumulating genetic damage tips cells toward cancer. The main drivers of that chronic damage are viral infections, alcohol, and metabolic disease, often acting in combination.
Chronic Hepatitis B and C
Hepatitis B virus (HBV) and hepatitis C virus (HCV) remain the leading causes of liver cancer globally. Both viruses drive cancer through persistent inflammation and impaired immune responses, but they use somewhat different tricks. HBV can integrate its DNA directly into the host genome early in infection, disrupting genes and destabilizing chromosomes. It also alters the cell’s epigenetic machinery and manipulates microRNA expression.3PubMed Central. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis HCV, which does not integrate into DNA, drives cancer partly by reprogramming how infected cells handle fat, promoting fatty buildup in the liver (steatosis) that adds to inflammatory damage.4PubMed Central. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma Both viruses also generate oxidative stress and hijack cellular signaling pathways through their own proteins.
Fatty Liver Disease and Metabolic Syndrome
The fastest-growing cause of HCC in many countries is non-alcoholic steatohepatitis (NASH), the inflammatory form of fatty liver disease closely tied to obesity and type 2 diabetes. Global epidemiological data from 2010 to 2019 showed NASH outpacing other causes of HCC in its rate of increase.5PubMed Central. Alarming increase of NASH as cause of liver cancer This trend is especially relevant in Western countries where hepatitis vaccination and antiviral treatment are reducing virus-related liver cancer, while obesity rates climb. Importantly, a subset of people with fatty liver disease can develop HCC even without cirrhosis, which makes screening in this group harder to target.
Alcohol, Obesity, and Genetic Vulnerability
Alcohol-related liver disease has long been a recognized route to HCC, but the relationship is not simply additive when other risk factors are present. Heavy drinking and severe obesity interact in a way that multiplies the risk. In one large study, men who both drank heavily and had a BMI of 30 or above faced roughly three and a half times the risk of developing HCC compared to what you would expect from adding those risks together.6PubMed. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men Similar synergistic effects have been observed between alcohol, tobacco use, and obesity.7PubMed. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma
Genetics can amplify the problem further. A common genetic variant in the PNPLA3 gene (carried by a large portion of the population, with especially high frequency in people of Latin American descent) interacts with both alcohol and obesity. People who carry two copies of this variant, drink excessively, and are obese face about a 30-fold increased risk of HCC compared to people without any of those three factors.8JAMA Network Open. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality The practical takeaway is that these risks do not just stack; they feed off each other.
Aflatoxin Exposure
In parts of sub-Saharan Africa and Southeast Asia, dietary exposure to aflatoxin B1 (a toxin produced by molds that grow on improperly stored grains and nuts) is a major contributor to liver cancer. Aflatoxin causes a specific mutation in the p53 tumor-suppressor gene, and when combined with chronic hepatitis B, the risk of HCC rises in a way that is more than just additive.9PubMed. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention Better food storage practices and reduced aflatoxin contamination in the food supply are effective prevention strategies in affected regions, though enforcement remains uneven.
Symptoms and Why They Come Late
Early-stage liver cancer rarely announces itself. The liver has no pain-sensing nerves in its interior, and it has enough reserve capacity to function even when a tumor is growing. Symptoms tend to appear only when the cancer is large enough to stretch the liver’s outer capsule, block bile ducts, or overwhelm the organ’s remaining function. When symptoms do develop, they commonly include:
- Upper abdominal pain: a dull ache or fullness below the right rib cage
- Unintentional weight loss: often the first thing patients notice in retrospect
- Loss of appetite and early fullness: the enlarged liver or tumor mass presses on the stomach
- Jaundice: yellowing of the skin and eyes from bile flow obstruction
- Ascites: fluid buildup in the abdomen, often a sign that the cancer has impaired liver function or raised pressure in the portal vein
Because these symptoms overlap with the cirrhosis many patients already have, they are easy to dismiss as progression of the underlying liver disease. This is exactly why surveillance programs for high-risk patients (typically ultrasound every six months) are so important: they aim to catch tumors when they are small and treatable, not when they are causing pain.
How Liver Cancer Is Diagnosed
Blood Biomarkers
AFP has been the traditional blood test used to screen for and help diagnose HCC, but its sensitivity when used alone is limited. A more effective approach combines AFP with two other markers: AFP-L3 (a specific sugar-modified fraction of AFP) and des-gamma-carboxy prothrombin (DCP, also known as PIVKA-II). A meta-analysis found that combining all three yielded about 88% sensitivity and 79% specificity for diagnosing HCC.10PubMed Central. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis In one study tracking patients over time, DCP was particularly good at gaining sensitivity as diagnosis approached, jumping from about 43% sensitivity a year before diagnosis to 74% at the time of diagnosis; when combined with AFP, sensitivity reached about 91%.11PubMed Central. Des-gamma-carboxy Prothrombin and Alpha fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma These markers complement each other because they are produced through different biological mechanisms.
Imaging and LI-RADS
Cross-sectional imaging with contrast-enhanced CT or MRI is central to liver cancer diagnosis. The Liver Imaging Reporting and Data System (LI-RADS) provides a standardized way for radiologists to categorize suspicious liver findings in patients already at risk for HCC. Observations are scored from LR-1 (definitely benign) to LR-5 (definitely HCC) based on features like arterial-phase hyperenhancement, washout appearance, and presence of a capsule.12PubMed Central. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review An LR-5 observation in a patient at risk for HCC can be treated as definitive for HCC without needing a biopsy, which is a relatively unusual situation in oncology where tissue diagnosis is typically required.
MRI tends to outperform CT in sensitivity for detecting HCC, particularly when used with liver-specific contrast agents.13PubMed Central. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma When a lesion falls into an indeterminate LI-RADS category (LR-3 or LR-4), clinicians may recommend a biopsy or short-interval follow-up imaging to resolve the uncertainty.
Pathology When Biopsy Is Needed
When imaging is inconclusive, tissue biopsy helps distinguish HCC from intrahepatic cholangiocarcinoma (the second most common primary liver cancer) and from metastatic disease. Under the microscope, HCC typically shows large cells with abundant pink cytoplasm arranged in thick cords, while cholangiocarcinoma forms glandular structures within a dense fibrous background.14JHEP Reports. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning Deep learning tools are now being developed to assist pathologists in making this distinction from routine biopsy slides, though clinical adoption is still early.
Staging and How It Guides Treatment
Unlike most cancers, where tumor size and spread alone dictate staging, liver cancer staging must also account for how well the liver itself is functioning. A small tumor in a severely cirrhotic liver is a very different clinical problem than the same-size tumor in a healthy liver. The Barcelona Clinic Liver Cancer (BCLC) system is the most widely used framework and integrates tumor characteristics, liver function, and overall patient fitness. It divides patients into stages from 0 (very early) through D (terminal), with each stage mapped to recommended treatment approaches.15PubMed Central. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system
At stage 0 and A (very early and early), curative treatments like surgical resection, transplant, and ablation are on the table. Stage B (intermediate) patients with multifocal disease but preserved liver function are typically treated with locoregional therapies. Stage C (advanced) patients with vascular invasion or cancer that has spread outside the liver receive systemic therapy. Stage D patients, with end-stage liver function and poor fitness, are candidates only for supportive care.
Surgical Options
Surgical resection (removing the tumor and a margin of surrounding liver tissue) is the first-line curative option for patients who have a single tumor, no significant portal hypertension, and good enough liver function for the organ to regenerate. The liver can regrow remarkably well, allowing surgeons to remove large portions when the remaining liver is healthy. The catch is recurrence: tumors come back in a substantial proportion of patients after resection, often because microscopic disease was already present in other parts of the liver at the time of surgery.
Liver transplantation offers what is arguably the most complete solution by removing both the cancer and the diseased liver. It gives the best long-term oncologic outcome because it eliminates the cirrhotic tissue where new cancers would otherwise develop.16PubMed Central. Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge The limiting factor is organ availability. In many health systems, wait times are long enough that patients’ cancers can progress beyond transplant criteria. Locoregional therapies are frequently used as a bridge to keep the cancer in check while patients wait for a donor organ.
Locoregional Therapies for Tumors That Cannot Be Surgically Removed
When surgery is not an option, several approaches treat the tumor directly without removing it. Radiofrequency ablation (RFA) uses a needle inserted through the skin to deliver heat that destroys tumor cells, and is most effective for small tumors. Transarterial chemoembolization (TACE) delivers chemotherapy directly into the artery feeding the tumor and then blocks that artery, hitting the cancer with a double blow of poison and starvation. Transarterial radioembolization (TARE), also known as Y90, embeds tiny radioactive microspheres in the tumor’s blood supply to deliver localized radiation.
A network meta-analysis comparing these approaches found that at one year, Y90 had a modest survival advantage over TACE, but all four modalities (including external radiation) produced similar overall survival at two and three years. TACE showed some advantage in progression-free survival at two years compared to RFA and radiation.17PubMed. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer – a systematic review and network meta-analysis of survival data Combining RFA with TACE for recurrent tumors has shown better response rates and tumor marker reduction than TACE alone.18PubMed Central. Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer
TARE has carved out a particular role in downsizing tumors to make patients eligible for transplant or resection, and is also used in patients with portal vein tumor thrombus, where TACE is often contraindicated. Both TACE and TARE are recommended for early HCC stages in patients unsuitable for surgery or ablation, and their survival benefits over best supportive care alone are well-established.19Efficacy and Relevance of Endoarterial Therapy (TACE/TARE) in Unresectable Liver Cancer. Efficacy and Relevance of Endoarterial Therapy (TACE/TARE) in Unresectable Liver Cancer
Systemic Therapy and the Immunotherapy Revolution
For patients with advanced HCC (BCLC stage C), the treatment landscape changed dramatically in 2020. Previously, sorafenib was the only first-line option. It blocks several growth-signaling pathways and was modestly effective, but the bar was low. Lenvatinib, another drug in the same class, was shown to be comparable to sorafenib and works by shutting down blood vessel growth through a slightly broader set of receptor targets.20PubMed Central. The action and resistance mechanisms of Lenvatinib in liver cancer
The real shift came with the combination of atezolizumab (an immune checkpoint inhibitor) and bevacizumab (which blocks the tumor’s blood supply). In the landmark IMbrave150 trial, this combination cut the risk of death by about 42% compared to sorafenib. One-year survival was roughly 67% with the combination versus about 55% with sorafenib, and the combination also significantly delayed disease progression.21PubMed. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma This rapidly became the new standard of care for first-line treatment of unresectable HCC.
Real-world data have largely confirmed the trial results. A meta-analysis of real-world studies found pooled 12-month overall survival of about 65%, with patients who had well-preserved liver function achieving a median overall survival around 21 months, closely matching the trial’s estimates.22JHEP Reports. Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence Patients with more compromised liver function tend to do worse, which underscores how intertwined liver health and cancer outcomes are in this disease. Other immunotherapy combinations (such as durvalumab plus tremelimumab) have since expanded the options further.
Prevention That Actually Works
Hepatitis B vaccination stands out as one of the most successful cancer-prevention strategies in medicine. Countries that introduced universal childhood vaccination have already seen drops in HCC incidence in the vaccinated generations, and vaccination remains a cornerstone of global efforts to eliminate hepatitis B-related liver cancer.23PubMed Central. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma
On the hepatitis C side, the introduction of direct-acting antiviral drugs (which can cure HCV infection in eight to twelve weeks) has had a measurable population-level effect. In Japan, newly diagnosed liver cancer among patients with chronic hepatitis C fell by about 69% over the decade following the shift to these modern treatments.24Open Forum Infectious Diseases. Reduction in the incidence of chronic hepatitis C, liver cancer, and related healthcare burden following the introduction of interferon-free direct-acting antiviral therapy in Japan: a national claims database study Curing the infection does not eliminate risk entirely (especially in patients who already have cirrhosis at the time of treatment), but it reduces it substantially enough that the effect is visible at the national level.
For the growing burden of fatty liver-related HCC, prevention is less straightforward. There is no vaccine and no single drug that reliably reverses NASH. Weight loss of around 7 to 10 percent of body weight can resolve the inflammatory component in many patients, and bariatric surgery shows promise in those with severe obesity, but sustaining these changes at a population level is the challenge. Given the synergistic interaction between obesity, alcohol, and genetic variants described earlier, reducing even one of those factors can disproportionately lower risk.
Who Gets Diagnosed Late and Why It Matters
Liver cancer outcomes vary dramatically by race, ethnicity, and socioeconomic status, and much of that variation traces not to biology but to the healthcare system. In the United States, Black and Latino patients are less likely to carry health insurance that covers the specialized treatments required, from surgical resection to transplantation. Even among insured patients, systemic biases play a role: people from minoritized groups are less likely to be referred for surveillance after a cirrhosis diagnosis and more likely to receive their liver cancer diagnosis at a later stage, when curative options have narrowed.25The Lancet Public Health. Mortality and disparities in liver cancer by county, race, and ethnicity in the USA, 2000–19: a systematic analysis of health disparities Late diagnosis is not just a medical problem; it is a systems problem.
Liver Cancer in Children
Pediatric liver cancer is rare and biologically distinct from adult HCC. The most common type in young children is hepatoblastoma, which does not arise from the chronic liver damage that characterizes adult disease. Recent research into the immune landscape of hepatoblastoma found that these tumors are heavily infiltrated by a specific type of immune cell (macrophages with particular checkpoint markers) rather than the T cells that dominate the immune response in many adult cancers.26SpringerLink (Cancer Immunology, Immunotherapy). High-plex imaging of hepatoblastoma and adjacent liver in pediatric patients reveals a predominant myeloid infiltrate expressing immune-checkpoints This matters because many current immunotherapies are designed to activate T cells, suggesting that different strategies may be needed for children with liver tumors. Treatment for hepatoblastoma typically centers on chemotherapy and surgical resection, with generally better survival rates than adult liver cancer.
Experimental Frontiers
One of the most talked-about experimental approaches is CAR T-cell therapy, where a patient’s own immune cells are engineered in a laboratory to recognize and attack cancer cells. CAR T therapy has been transformative in certain blood cancers, but applying it to solid tumors like HCC has proved far more difficult. The tumor’s local environment actively suppresses immune cells, the targets on HCC cells vary from tumor to tumor (and even within a single tumor), and the engineered cells often become exhausted before finishing their work. There is also the concern that any surface marker shared between cancer cells and healthy liver cells could cause serious off-target liver damage.27PubMed Central. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand? Multiple clinical trials are working on these obstacles, but CAR T therapy for liver cancer remains firmly in the investigational stage.